Showing 331-340 of 356 results for "".
- Delgocitinib for CHE Gains EC Approval, FDA NDA Acceptancehttps://practicaldermatology.com/news/delgocitinib-che-gains-ec-approval-fda-nda-acceptance/2468259/Delgocitinib cream 20 mg/g (2%) reached major milestones in both the United States and Europe, LEO Pharma Inc. announced. The US Food and Drug Administration (FDA) accepted a filing for a New Drug Application (NDA) for LEO Pharma’s AnzupgoÒ for the treatment of adults with moderate-to-seve
- Study Explores Potential of GLP-1 Agonists for Skin Disease Managementhttps://practicaldermatology.com/news/study-explores-potential-glp-1-agonists-skin-disease-management/2468016/Recent research highlights the potential of GLP-1 agonists in managing dermatological conditions such as psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease, especially in patients with obesity or type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 (G
- Study: Sodium Levels Linked to Atopic Dermatitishttps://practicaldermatology.com/news/study-sodium-levels-linked-atopic-dermatitis/2466978/High sodium levels could be linked to increased risk of developing atopic dermatitis, according to a JAMA Dermatology study published June 5. A cross-sectional study of 215,832 adults found that a 1-g higher estimated 24-hour urine sodium excretion was associated with 11% higher odds of at
- DISCREET: Apremilast Effective for Genital Psoriasis for Treatment Nonrespondershttps://practicaldermatology.com/news/discreet/2462239/Apremilast was efficacious in reducing the symptoms of genital psoriasis (G-PsO) in patients who didn't respond to topical treatments or who were not adequately controlled by topical therapy, new research indicates. DISCREET aimed to evaluate the efficacy and safety of apremil
- Study: Transgender Individuals Experience Stigma, Treatment Barriershttps://practicaldermatology.com/news/lived-experience-of-acne-and-acne-treatment-in-transgender-patients/2462206/New research sheds light on the lived experiences of transgender individuals who have acne. "While acne is common in transgender and gender-diverse people and is associated with gender-affirming hormone therapy, little research has examined these factors and their impact in g
- MHRA Grants Marketing Authorization for Incyte's Opzelura Cream for Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescentshttps://practicaldermatology.com/news/mhra-grants-marketing-authorization-for-incytes-opzelura-cream-for-non-segmental-vitiligo-with-facial-involvement-in-adults-and-adolescents/2461838/The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing clearance for Incyte’s Opzelura (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. “Today&rs
- FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with DEBhttps://practicaldermatology.com/news/fda-approves-first-topical-gene-therapy-for-treatment-of-wounds-in-patients-with-deb/2461732/The U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) g
- Incyte Scores Vitiligo Nod for Opzelura Cream in Europehttps://practicaldermatology.com/news/incyte-scores-nod-for-opzelura-cream-for-vitiligo-in-europe/2461674/The European Commission (EC) has granted a marketing authorization for Opzelura (ruxolitinib) cream15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. The selective JAK1/JAK2 inhibi
- Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous BCChttps://practicaldermatology.com/news/sirnaomics-achieves-100-complete-response-in-phase-ii-clinical-trial-of-stp705-for-treatment-of-cutaneous-bcc/2461319/Patients receiving the 180μg dose level in the Phase II clinical trial of STP705 for the treatment of cutaneous basal cell carcinoma (BCC) achieved a 100% complete response, with no safety signals, Sirnaomics reports. STP705 is a siRNA (small inte
- Tarek El Hoss Named Sr. Vice President of Market Development and Sales at MedXhttps://practicaldermatology.com/news/tarek-el-hoss-named-sr-vice-president-of-market-development-and-sales-at-medx/2461287/Tarek El Hoss is MedX Health Corp.’s New Senior Vice President, Market Development and Sales. Mr. El Hoss will oversee strategic global growth initiatives and will be responsible for the deployment of market development strategies to impact immediate revenue generation and g